Shots: • Galafold is a first precision and oral drug (Q2D) for 348 amenable galactosidase alpha gene (GLA) variants to treat Fabry in U.S. • The approval was under Subpart […]readmore
Tags : Fabry Disease
Shots: Alnylam’s siRNA molecule Onpattro receives FDA approval for fatal genetic disorder polyneuropathy caused by hereditary transthyretin-mediated amyloidosis (hATTR) Approval is based on results from Ph III APOLLO study involving […]readmore
Shots: The approval is based on P-III FACET or Study 011 results assessing Galafold (150mg) in patient with Fabry Disease, evaluating its safety and efficacy The FACET or Study 011 […]readmore